News stories about CareDx (NASDAQ:CDNA) have been trending somewhat positive on Tuesday, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. CareDx earned a daily sentiment score of 0.09 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 47.3698149307679 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:

Shares of CDNA opened at $17.03 on Tuesday. CareDx has a 12 month low of $1.81 and a 12 month high of $18.05. The firm has a market cap of $628.06 million, a PE ratio of -22.12 and a beta of 0.51. The company has a current ratio of 2.16, a quick ratio of 1.83 and a debt-to-equity ratio of 0.46.

CareDx (NASDAQ:CDNA) last announced its quarterly earnings results on Thursday, August 9th. The company reported ($0.04) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.07) by $0.03. CareDx had a negative net margin of 121.92% and a negative return on equity of 108.99%. The company had revenue of $17.82 million for the quarter, compared to analyst estimates of $15.30 million. equities research analysts forecast that CareDx will post -0.94 earnings per share for the current fiscal year.

Several research analysts have weighed in on CDNA shares. ValuEngine upgraded shares of CareDx from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. BidaskClub upgraded shares of CareDx from a “buy” rating to a “strong-buy” rating in a research note on Friday, May 4th. HC Wainwright reiterated a “buy” rating and issued a $14.00 price objective on shares of CareDx in a research note on Friday, May 11th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $17.00 price objective on shares of CareDx in a research note on Wednesday, June 6th. Finally, TheStreet lowered shares of CareDx from a “c-” rating to a “d” rating in a research note on Monday, June 11th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and two have given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $12.90.

In other news, COO Mitchell J. Nelles sold 39,649 shares of the stock in a transaction on Monday, July 2nd. The shares were sold at an average price of $12.48, for a total transaction of $494,819.52. Following the transaction, the chief operating officer now owns 89,639 shares in the company, valued at approximately $1,118,694.72. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Sasha King sold 9,458 shares of the stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $14.03, for a total transaction of $132,695.74. Following the transaction, the insider now owns 71,792 shares in the company, valued at approximately $1,007,241.76. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 61,607 shares of company stock worth $838,015. 3.40% of the stock is currently owned by company insiders.

About CareDx

CareDx, Inc, a transplant diagnostics company, together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients worldwide. It operates through two segments, Post-Transplant Diagnostics and Pre-Transplant Diagnostics.

Further Reading: Technical Analysis

Insider Buying and Selling by Quarter for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.